Some weeks exceed expectations
Share this bulletin with your team
Ethics declarations Disclosure Avery Brown, Helena Sergent, Alexander Hien Vu, Helen Liu, Jason Fisher, Eduardo Somoza, Tony Mei, Jeffrey Lipman, Julia Park, Patricia Chui, John Saunders, Marina Kurian, Loic Tchokouani, George Ferzli, Christine Ren-Fielding, Manish Parikh, Megan Jenkins have no conflicts of interest or financial ties to disclose
Neither medication is a magic pill
By combining all three receptor targets, Retatrutide allows researchers to study the convergence of incretin biology and glucagon-driven energy expenditure in a single compound, opening research questions that cannot be addressed with any dual or single-receptor agonist
Any marketing suggesting FDA approval or endorsement for this product is misleading